Barry D Greenberg1, Corinne Pettigrew2, Anja Soldan2, Jiangxia Wang2, Mei-Cheng Wang2, Jacqueline A Darrow2, Marilyn S Albert2, Abhay Moghekar2. 1. From the Department of Neurology (B.D.G., C.P., A.S., J.A.D., M.S.A., A.M.), Johns Hopkins University School of Medicine; and Department of Biostatistics (J.W., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. bgreen45@jhmi.edu. 2. From the Department of Neurology (B.D.G., C.P., A.S., J.A.D., M.S.A., A.M.), Johns Hopkins University School of Medicine; and Department of Biostatistics (J.W., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Abstract
BACKGROUND AND OBJECTIVES: This study aimed to examine whether baseline CSF measures of Alzheimer disease (AD)-related pathology are associated with the time to onset of mild cognitive impairment (MCI) and whether these associations differ by age, sex, Apolipoprotein E (ApoE4) status, and proximal (≤7 years) vs distal (>7 years) time to symptom onset. METHODS: Measures of amyloid (Aβ1-42 and Aβ1-40), phospho-tau (ptau181), and total tau (t-tau) were determined from CSF samples obtained at baseline from participants in an ongoing longitudinal project, known as the Biomarkers for Older Controls at Risk for Alzheimer Disease study (BIOCARD) study. The fully automated, Lumipulse G immunoassay was used to analyze the specimens. Cox regression models were used to examine the relationship of baseline biomarker levels with time to symptom onset of MCI and interactions with age, sex, and ApoE allelic status in subjects who progressed from normal cognition to MCI. RESULTS: Analyses included 273 participants from the BIOCARD cohort, who were cognitively normal and predominantly middle-aged at baseline, and have been followed for an average of 16 years (max = 23.6). During follow-up, 94 progressed to MCI (median time to symptom onset = 6.9 years). In Cox regression models, elevated ptau181 and t-tau levels were associated with time to MCI symptom onset if it occurred within 7 years of baseline (HR 1.386 and 1.329; p = 0.009 and 0.017, respectively), while a lower Aβ42/Aβ40 ratio was associated with symptom onset if it occurred >7 years from baseline (HR 0.596, p = 0.003). There were also significant 3-way CSF × age × sex interactions for ptau181 and Aβ42/Aβ40, with follow-up analyses indicating that associations between these biomarkers and progression to MCI were stronger among men than among women, but this difference between sexes diminished with increasing age. DISCUSSION: The lengthy follow-up of BIOCARD participants permitted an examination of time-varying associations between CSF AD biomarkers with MCI symptom onset and the influence of sex, baseline age, and ApoE4 genotype on these associations. These factors may inform clinical trial enrollment strategies, or trial duration and outcomes, which may use these measures as surrogate markers of treatment response.
BACKGROUND AND OBJECTIVES: This study aimed to examine whether baseline CSF measures of Alzheimer disease (AD)-related pathology are associated with the time to onset of mild cognitive impairment (MCI) and whether these associations differ by age, sex, Apolipoprotein E (ApoE4) status, and proximal (≤7 years) vs distal (>7 years) time to symptom onset. METHODS: Measures of amyloid (Aβ1-42 and Aβ1-40), phospho-tau (ptau181), and total tau (t-tau) were determined from CSF samples obtained at baseline from participants in an ongoing longitudinal project, known as the Biomarkers for Older Controls at Risk for Alzheimer Disease study (BIOCARD) study. The fully automated, Lumipulse G immunoassay was used to analyze the specimens. Cox regression models were used to examine the relationship of baseline biomarker levels with time to symptom onset of MCI and interactions with age, sex, and ApoE allelic status in subjects who progressed from normal cognition to MCI. RESULTS: Analyses included 273 participants from the BIOCARD cohort, who were cognitively normal and predominantly middle-aged at baseline, and have been followed for an average of 16 years (max = 23.6). During follow-up, 94 progressed to MCI (median time to symptom onset = 6.9 years). In Cox regression models, elevated ptau181 and t-tau levels were associated with time to MCI symptom onset if it occurred within 7 years of baseline (HR 1.386 and 1.329; p = 0.009 and 0.017, respectively), while a lower Aβ42/Aβ40 ratio was associated with symptom onset if it occurred >7 years from baseline (HR 0.596, p = 0.003). There were also significant 3-way CSF × age × sex interactions for ptau181 and Aβ42/Aβ40, with follow-up analyses indicating that associations between these biomarkers and progression to MCI were stronger among men than among women, but this difference between sexes diminished with increasing age. DISCUSSION: The lengthy follow-up of BIOCARD participants permitted an examination of time-varying associations between CSF AD biomarkers with MCI symptom onset and the influence of sex, baseline age, and ApoE4 genotype on these associations. These factors may inform clinical trial enrollment strategies, or trial duration and outcomes, which may use these measures as surrogate markers of treatment response.
Authors: June Kaplow; Manu Vandijck; Julia Gray; Michio Kanekiyo; Els Huyck; C J Traynham; Rianne Esquivel; Anne M Fagan; Johan Luthman Journal: Alzheimers Dement Date: 2020-01 Impact factor: 21.566
Authors: Anja Soldan; Corinne Pettigrew; Qing Cai; Mei-Cheng Wang; Abhay R Moghekar; Richard J O'Brien; Ola A Selnes; Marilyn S Albert Journal: JAMA Neurol Date: 2016-06-01 Impact factor: 18.302
Authors: Shahram Oveisgharan; Zoe Arvanitakis; Lei Yu; Jose Farfel; Julie A Schneider; David A Bennett Journal: Acta Neuropathol Date: 2018-10-17 Impact factor: 17.088
Authors: Carol K Chan; Anja Soldan; Corinne Pettigrew; Mei-Cheng Wang; Jiangxia Wang; Marilyn S Albert; Paul B Rosenberg Journal: Int Psychogeriatr Date: 2018-10-10 Impact factor: 3.878
Authors: Rachel F Buckley; Elizabeth C Mormino; Jasmeer Chhatwal; Aaron P Schultz; Jennifer S Rabin; Dorene M Rentz; Diler Acar; Michael J Properzi; Julien Dumurgier; Heidi Jacobs; Teresa Gomez-Isla; Keith A Johnson; Reisa A Sperling; Bernard J Hanseeuw Journal: Neurobiol Aging Date: 2019-03-07 Impact factor: 4.673
Authors: Ronald C Petersen; Ronald G Thomas; Paul S Aisen; Richard C Mohs; Maria C Carrillo; Marilyn S Albert Journal: Neurology Date: 2017-04-05 Impact factor: 9.910
Authors: Ashvini Keshavan; Henrietta Wellington; Zhongbo Chen; Ayesha Khatun; Miles Chapman; Melanie Hart; David M Cash; William Coath; Thomas D Parker; Sarah M Buchanan; Sarah E Keuss; Matthew J Harris; Heidi Murray-Smith; Amanda Heslegrave; Nick C Fox; Henrik Zetterberg; Jonathan M Schott Journal: Alzheimers Dement (Amst) Date: 2021-02-06
Authors: Jingqin Luo; Folasade Agboola; Elizabeth Grant; Colin L Masters; Marilyn S Albert; Sterling C Johnson; Eric M McDade; Jonathan Vöglein; Anne M Fagan; Tammie Benzinger; Parinaz Massoumzadeh; Jason Hassenstab; Randall J Bateman; John C Morris; Richard J Perrin; Jasmeer Chhatwal; Mathias Jucker; Bernardino Ghetti; Carlos Cruchaga; Neill R Graff-Radford; Peter R Schofield; Hiroshi Mori; Chengjie Xiong Journal: Neurology Date: 2020-09-01 Impact factor: 11.800